Advertisement
Journal of Oncology Practice  
Search for:
Limit by:
  Browse by Topic or Issue
Home Search or Browse JOP Subscriptions PDA Services E-mail Alerts Customer Service

Journal of Oncology Practice, Vol 5, No 1 (January), 2009: pp. 40-41
© 2009 American Society of Clinical Oncology.
DOI: 10.1200/JOP.0912504

This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Policy in Focus

The Genetic Information Nondiscrimination Act: A First Step Toward Protecting Americans From Misuse of Genetic Information


Figure 1

President George W. Bush signed the Genetic Information Nondiscrimination Act (GINA) into law on May 21, 2008, with the explanation that "it protects our citizens from having genetic information misused, and this bill does so without undermining the basic premise of the insurance industry." At the bill signing ceremony, President Bush also offered a special thank you to Senator Ted Kennedy for more than a decade of work on the legislation.

Advocates for the new law heralded their success, achieved after 13 years of hard work to secure serious consideration and passage. Proponents of the new law believe it will offer substantial protection against discrimination on the basis of genetic information in issuance or premium setting in health insurance as well as protection against discrimination in employment. The law will eliminate concerns among Americans about the ramifications of seeking genetic testing and counseling, and will also foster aggressive efforts to develop and disseminate new genetic tests. Supporters of the new law believe that its passage sets the stage for more rapid progress toward an era of personalized medicine.

GINA defines genetic information as an individual's genetic tests, the genetic tests of family members (up to fourth-degree relatives), a manifestation of disease in a family member, or participation of an individual or family member in research that includes genetic testing.

The health insurance provisions of GINA will go into effect 12 months after enactment, with the employment provisions following 6 months later, or 18 months after enactment.


    What Does GINA Do?
 Top
 What Does GINA Do?
 What Won't GINA Do?
 Are There Any Shortcomings...
 Conclusion
 
GINA will:

  • Prohibit group and individual health insurers from using an individual's genetic information to determine eligibility for insurance or premiums for insurance;
  • Block an insurer from requesting or requiring an individual to take a genetic test;
  • Prohibit employers from using genetic information in making decisions related to hiring, firing, or other terms of employment;
  • Prevent employers from requesting, requiring, or purchasing genetic information about employees or their family members.


    What Won't GINA Do?
 Top
 What Does GINA Do?
 What Won't GINA Do?
 Are There Any Shortcomings...
 Conclusion
 
GINA does not mandate coverage for any particular genetic test, nor does it require coverage for any treatment. Although the law would prevent underwriting on the basis of genetic information, it would not prevent medical underwriting on the basis of current health condition. Neither would the law cover life, disability, or long-term care insurance.

The new law will not prevent health care providers from recommending genetic tests to their patients. In fact, its supporters believe that providers will be more aggressive in recommending tests if they can assure their patients that they are protected from discrimination based on the genetic information that might result from testing.


    Are There Any Shortcomings to GINA?
 Top
 What Does GINA Do?
 What Won't GINA Do?
 Are There Any Shortcomings...
 Conclusion
 
Critics of the law have suggested that GINA underscores the limits of an incremental approach to health care reform and note that GINA would provide an individual with a family history of cancer or an increased genetic risk of cancer insurance protection, while offering no similar protection to one already diagnosed with cancer. For these critics, the solution is elimination of medical underwriting.

Champions of GINA concluded that comprehensive insurance reform, which would have included elimination of medical underwriting, was not a realistic possibility when GINA was introduced. In the face of that challenge, they made a conscious and deliberate decision to pursue an achievable goal—the protections offered by GINA—a goal that nonetheless took 13 years to achieve. Some also note that GINA does not address the additional regulatory issues related to genetic testing, including the need for greater oversight to ensure the quality and reliability of genetic tests. These regulatory steps are considered important to ensure that genetic tests are reliable, affordable, and used broadly in connection with genetic counseling to improve the quality of health care.


    Conclusion
 Top
 What Does GINA Do?
 What Won't GINA Do?
 Are There Any Shortcomings...
 Conclusion
 
Those who began the fight for a genetic nondiscrimination law more than a decade ago have remained steadfast in their support of the effort and in their belief that it will provide meaningful protections to Americans in a genomic age. The Coalition for Genetic Fairness, a key player in enactment of the legislation, remains dedicated to smooth implementation of the law. The Coalition describes the law as the first civil rights law of the new millennium and offers materials to guarantee adherence to the new law at http://www.geneticfairness.org/.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

About
JOP
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2009 by the American Society of Clinical Oncology, Online ISSN: 1935-469X. Print ISSN: 1554-7477
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JOP Online